New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
04:55 EDTSTAA, STAA, STAA, VTL, VTL, VTL, ANAC, ANAC, ANAC, PTCT, PTCT, PTCT, SGMO, SGMO, SGMO, RNA, RNA, RNA, BLUE, BLUE, BLUE, BIND, BIND, BIND, FCSC, FCSC, FCSC, CRDC, CRDC, CRDC, DRTX, DRTX, DRTXWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
News For DRTX;CRDC;FCSC;BIND;BLUE;RNA;SGMO;PTCT;ANAC;VTL;STAA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
19:18 EDTSGMOOn The Fly: After Hours Movers
UP AFTER EARNINGS: Limelight Networks (LLNW), up 20%... Akamai Technologies (AKAM), up 15.7%... Marketo (MKTO), up 9.9%... Paycom Software (PAYC), up 13.8%... A10 Networks (ATEN), up 7.3%... Prospect Capital (PSEC), up 8.6%... Nuance Communications (NUAN), up 6.5%... Panera Bread (PNRA), up 2.8%. ALSO HIGHER: Empire District Electric (EDE), up 14.8% after Algonquin Power will acquire the company for $34.00 per share. DOWN AFTER EARNINGS: SolarCity (SCTY), down 32.6%... LeapFrog (LF), down 2%... Orion Energy Systems (OESX), down 23.8%... Seattle Genetics (SGEN), down 3.6%... Sangamo Biosciences (SGMO), down 7.1%... Disney (DIS), down 3.4%... Demandware (DWRE), down 2.6%. ALSO LOWER: Sunrun (RUN) is down 6.9%, Solaredge Technologies (SEDG) is down 6.6%, SunEdison (SUNE) is down 5.9%, Canadian Solar (CSIQ) is down 2.9%, SunPower (SPWR) is down 2.9%, and Tesla (TSLA) is down 2.2% following SolarCity's fourth quarter results.
16:08 EDTSGMOSangamo sees FY16 revenue $20M-$25M, consensus $34.23M
Subscribe for More Information
16:07 EDTSGMOSangamo reports Q4 EPS (20c), consensus (21c)
Subscribe for More Information
07:03 EDTSTAAMemira to provide STAAR's phakic intraocular lenses primary option
Subscribe for More Information
February 8, 2016
10:17 EDTPTCTSarepta approval seen as 'long shot' as FDA pushes back decision
Shares of drugmaker Sarepta Therapeutics (SRPT) took a dive in morning trading after the company said the U.S. Food and Drug Administration delayed a decision on eteplirsen for the treatment of Duchenne muscular dystrophy. WHAT'S NEW: Sarepta announced that the FDA has pushed out the the Prescription Drug User Fee Act, or PDUFA, date for eteplirsen for the treatment of Duchenne muscular dystrophy to May 26. The previous PDUFA date for the eteplirsen new drug application, or NDA, was originally set for late February. FDA POSTPONEMENT: The FDA notified Sarepta that it's submission of 4-year clinical data, including additional six minute walk test and loss of ambulation data compared to historical control, was designated as a "major amendment" to the NDA and that the PDUFA goal date was extended to allow for a full review of the submission. The FDA previously granted eteplirsen Priority Review status, as well as Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Status to eteplirsen. WHAT'S NOTABLE: In late January, the FDA postponed a meeting of its advisory committee to review the Sarepta drug due to an inclement weather forecast for Washington D.C. LONG SHOT: Piper Jaffray analyst Edward Tenthoff told investors in a note that the FDA's PDUFA date postponement for eteplirsen is "not surprising" following the delay of the January 22 AdCom due to weather. Tenthoff also noted that a new AdCom has yet to be scheduled. The analyst continues to see eteplirsen accelerated approval by the new PDUFA date as a "long shot." He believes that the panel discussion will be a "plea from the community" to approve something for DMD and that members will not be asked to vote on drug approval. Tenthoff has a Neutral rating and $15 price target on Sarepta. OTHERS TO WATCH: Other companies developing treatments for Duchenne muscular dystrophy include BioMarin (BMRN) and PTC Therapeutics (PTCT). PRICE ACTION: Sarepta is down 9.5% in morning trading to $11.06.
07:06 EDTSGMOSangamo announces FDA clearance of IND application for SB-318
Subscribe for More Information
February 4, 2016
16:25 EDTCRDCCardica reports Q2 EPS (5c), consensus (5c)
Subscribe for More Information
February 3, 2016
10:00 EDTBLUEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Capella Education (CPLA) initiated with an Outperform at Credit Suisse... DeVry (DV) initiated with an Outperform at Credit Suisse... Gilead (GILD) initiated with a Buy at Standpoint Research... Grand Canyon (LOPE) initiated with a Neutral at Credit Suisse... Hannon Armstrong (HASI) initiated with an Equal Weight at Morgan Stanley... Houghton Mifflin (HMHC) initiated with an Outperform at Credit Suisse... Mediaset (MDIUY) initiated with a Buy at Jefferies... Palo Alto (PANW) initiated with a Buy at Maxim... Splunk (SPLK) initiated with a Buy at Maxim... Strayer (STRA) initiated with a Neutral at Credit Suisse... Tableau (DATA) initiated with a Sell at Maxim... Tesla (TSLA) initiated with a Sell at Berenberg... WisdomTree (WETF) initiated with an Outperform at Northland... bluebird bio (BLUE) initiated with an Outperform at Leerink.
08:02 EDTBLUEbluebird bio initiated with an Outperform at Leerink
Subscribe for More Information
February 2, 2016
08:36 EDTSGMOPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
07:15 EDTFCSCCanaccord to hold a conference
Subscribe for More Information
February 1, 2016
09:43 EDTFCSCFibrocell Science initiated with a Buy at Canaccord
Subscribe for More Information
January 27, 2016
08:16 EDTFCSCFibrocell highlights pipeline accomplishments
Subscribe for More Information
08:01 EDTBINDBIND says iNSITE 1 trial fully enrolled, data expected by end of Q1
BIND Therapeutics announced that the iNSITE 1 trial in non-small cell lung cancer with squamous histology is fully enrolled and data is expected to be available by the end of the first quarter of 2016. In addition, the company announced that the iNSITE 2 trial in patients with advanced cervical cancer and head and neck cancer has completed enrollment of at least 20 patients in each cohort in the first stage of the trial. A decision is expected on whether to advance to the second stage of the study for head and neck cancer by the end of the first quarter of 2016 and early in the second quarter of 2016 for the cervical cancer cohort. Lastly, the company announced that enrollment is being discontinued in the cholangiocarcinoma and bladder cancer cohorts in the iNSITE 2 trial due to slower than anticipated enrollment.
January 26, 2016
14:27 EDTANACAnacor shares defended at Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use